Department of Pharmacology Archives
Collaboration seeks to develop new therapies for bone, other diseases
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
VUMC study shifts thinking on how bone fractures heal
Aug. 13, 2015—New findings show that fibrin, a protein that was thought to play a key role in fracture healing, is not required, shifting understanding of how fractures heal.
Bridging the antibiotic gap
Aug. 7, 2015—Vanderbilt researchers have discovered how certain molecules with antibiotic properties are synthesized, findings that could lead to new drugs that overcome the increased antibiotic resistance in bacteria.
How to trick a wily virus
Jul. 24, 2015—Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus.
Lit up COX-2 cancer probe
Jun. 17, 2015—A new imaging probe developed by Vanderbilt investigators enhances tumor visibility and has broad applications in diagnosing and monitoring patients with cancer.
New strategy to combat HIV
Jun. 12, 2015—Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.
Findings reveal new target in quest to ease schizophrenia
May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
Neurofibromin fine-tunes bone growth
May. 6, 2015—The protein neurofibromin acts as a brake in a signaling pathway that is important in bone development, Vanderbilt researchers have discovered.
Lecture explores efforts to move pharmacogenetics into the clinic
Apr. 23, 2015—Preemptive genotyping: It sounds like a surprise attack, and it is.
Cancer signaling pathway blocker
Apr. 3, 2015—Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer.
Pharmacogenomics expert set for Wilkinson Lecture
Apr. 2, 2015—Mary Relling, Pharm.D., chair of the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital in Memphis, will deliver this year’s Grant R. Wilkinson Distinguished Lecture in Clinical Pharmacology on Thursday, April 9.
New view of dopamine heteromers
Jan. 23, 2015—Although heteromeric dopamine receptors composed of both D1 and D2 subunits have been proposed to play a role in depression and schizophrenia, recent studies suggest these heteromers do not exist.
